Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3507360 | 0.92 | AR (0.59) | ARKCNH2SRD5A2 | |
| SCHEMBL3505656 | 0.91 | AR (0.58) | ARKCNH2SRD5A2 | |
| SCHEMBL3506725 | 0.91 | AR (0.58) | ARKCNH2SRD5A2 | |
| SCHEMBL3506893 | 0.91 | AR (0.58) | ARKCNH2SRD5A2 | |
| SCHEMBL3507380 | 0.91 | AR (0.57) | ARKCNH2SRD5A2 | |
| SCHEMBL3506550 | 0.90 | AR (0.58) | ARKCNH2SRD5A2 | |
| SCHEMBL3506849 | 0.90 | AR (0.54) | ARKCNH2SRD5A2 | |
| SCHEMBL3506208 | 0.90 | AR (0.56) | ARKCNH2SRD5A2 | |
| SCHEMBL3506031 | 0.90 | AR (0.56) | ARKCNH2SRD5A2 | |
| SCHEMBL4660334 | 0.90 | AR (0.56) | ARKCNH2SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641535-A4 | 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2008-05-14 | — | — | EP | claimed |
| US-20060287326-A1 | 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-12-21 | — | — | US | claimed |
| EP-1641535-A2 | 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| WO-2005005380-A2 | 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | claimed |
| US-7696217-B2 | 17-acetamido-4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20060287326-A1 | 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287326-A1 | 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators | AR, NR5A1, NR3C1 | AR 1/4885KCNH2 4648/4885SRD5A2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.